Catalent Commits $175 Million to Upgrading Kentucky Facility

Article

Investment will grow manufacturing capabilities at Winchester site

Catalent, a contract development and manufacturing organization (CDMO), has started a $175 million project to expand its flagship US manufacturing facility for large scale oral dose forms in Winchester, KY. Two new buildings, which are expected to be completed by January 2024, will add 107,000 square feet to the site’s manufacturing footprint.

The expansion, the CDMO says, is expected to expand the site’s material handling capabilities and containment vault, provide additional laboratory space, and add additional capacity for existing turnkey operations, including dual fill encapsulation and pan coating, along with a variety of packaging solutions and analytical services. These latest expansions follow a doubling of the site’s footprint to 190,000 square feet in 2015, and a $40 million investment in 2019 that saw the installation of new equipment for stick pack dosage manufacturing, integrated packaging lines, as well as expanded roller compaction and fluid bed capacity.

“We are witnessing a broad increase in demand for manufacturing, and the nature of the development pipeline being strong in both oncology treatments and complex molecules, necessitates the expansion of specific capabilities in areas such as highly potent materials handling,” comments Aris Gennadios, PhD, president of softgel & oral technologies at Catalent. “Our Winchester site has a rich history in the successful commercialization of new products, and this expansion is the latest in a series of strategic investments, totaling hundreds of millions of dollars, to ensure that the current and future needs of our customers can be met.”

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.